News | January 25, 2022
USFDA rejects Merck’s gefapixant; gain approval in Japan
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Yoga helps to build a strong immune system and daily breathing regime of 10-minute helps in the long run
Industry Report highlights the opportunities and need for multiple sectoral collaboration through 12 actionable recommendations under 6 thematic areas
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
The brand is now available pan-India through their distribution partner
The Health ID will allow users to connect with different healthcare providers and enable a consent-based sharing of personal health records
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
Oravax's oral VLP vaccine in development targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially more effective against current and future variants of the Covid-19 virus
Subscribe To Our Newsletter & Stay Updated
